Abstract
Hypermenorrhea in female patients with severe thrombocytopenia has been one of the most difficult complications to manage. In this study, administration of LH-RH analogue (200 μg/day, subcutaneous injection) was tried to control hypermenorrhea in three patients with aplastic anemia, Evans' syndrome and acute myelofibrosis, respectively.
LH-RH analogue suppressed the menstrual cycle and subsequently stopped menstruation with certainty and safety in these three patients. The amenorrhea induced by LH-RH analogue was reversible even after long term administration. Occasionally, a short term administration of estrogen-progestin combinations in addition to LH-RH analogue was helpful to reduce the genital bleeding immediately, since it took a few weeks to accomplish the amenorrheal status by LH-RH analogue alone.
During the treatment by LH-RH analogue, the suppression of menstrual cycle was confirmed by poor response of LH and FSH to regular LH-RH.
So far no noticable side effect of LH-RH analogue has been noted.
LH-RH analogue appeared most useful to treat the hypermenorrhea caused by thrombocytopenia.
